<div id="readability-page-1"><p>Fmr LLC lessened its position in  Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 11,076,445 shares of the biopharmaceutical company's stock after selling 45,207 shares during the period. Fmr LLC owned 10.42% of Intra-Cellular Therapies worth $925,105,000 at the end of the most recent reporting period.</p><ul><li>MarketBeat Week in Review – 01/13 - 01/17</li></ul><p>A number of other hedge funds have also recently modified their holdings of ITCI. Vanguard Group Inc. raised its holdings in  Intra-Cellular Therapies by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 9,721,360 shares of the biopharmaceutical company's stock worth $811,928,000 after purchasing an additional 93,107 shares in the last quarter.  Norges Bank bought a new position in  Intra-Cellular Therapies in the fourth quarter worth about $268,347,000.  State Street Corp raised its stake in  Intra-Cellular Therapies by 3.1% in the third quarter. State Street Corp now owns 1,858,915 shares of the biopharmaceutical company's stock worth $136,017,000 after buying an additional 56,664 shares in the last quarter.  Franklin Resources Inc. lifted its holdings in  Intra-Cellular Therapies by 1.3% in the fourth quarter. Franklin Resources Inc. now owns 1,776,880 shares of the biopharmaceutical company's stock worth $148,405,000 after buying an additional 23,594 shares during the period.  Finally, Geode Capital Management LLC boosted its position in  Intra-Cellular Therapies by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,716,829 shares of the biopharmaceutical company's stock valued at $143,434,000 after acquiring an additional 8,528 shares in the last quarter. Hedge funds and other institutional investors own  92.33% of the company's stock. </p><h2>Intra-Cellular Therapies Stock Performance</h2><p>Shares of ITCI stock opened at $131.87 on Tuesday. Intra-Cellular Therapies, Inc. has a twelve month low of $64.09 and a twelve month high of $131.98. The stock has a market cap of $14.05 billion, a P/E ratio of -151.57 and a beta of 0.69. The stock has a 50 day moving average of $129.71 and a 200 day moving average of $102.19. </p><ul><li>Is Johnson &amp; Johnson Stock Set to Reward Long-Term Holders?</li></ul><p>Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last posted its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The firm had revenue of $199.22 million for the quarter, compared to analysts' expectations of $205.08 million.  On average, research analysts predict that  Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year. </p><h2>Wall Street Analyst Weigh In</h2><p>A number of equities research analysts have weighed in on ITCI shares. Cantor Fitzgerald  restated a &#34;neutral&#34; rating and issued a $132.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 2nd. Royal Bank of Canada  restated a &#34;sector perform&#34; rating and issued a $132.00 price target (up previously from $108.00) on shares of Intra-Cellular Therapies in a research note on Wednesday, January 22nd. Needham &amp; Company LLC  reaffirmed a &#34;hold&#34; rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Saturday. They issued a &#34;hold&#34; rating on the stock. Finally, Baird R W downgraded Intra-Cellular Therapies from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, January 13th. Eleven research analysts have rated the stock with a hold rating and five have issued  a buy rating to the company. Based on data from MarketBeat, the stock  has an average rating of &#34;Hold&#34; and a consensus price target of $106.23.</p><ul><li>Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals</li></ul><p><b>Get Our Latest Stock Report on Intra-Cellular Therapies</b></p><h2>Intra-Cellular Therapies Company Profile</h2> (Free Report)<p>Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Intra-Cellular Therapies</li><li>What Does a Gap Up Mean in Stocks? How to Play the Gap</li><li>Options Activity Points to More Volatility for Palantir Stock</li><li>Election Stocks: How Elections Affect the Stock Market</li><li>NVIDIA Stock: Oversold, Undervalued — How Low Can It Go?</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>MicroStrategy Sees Insider Buy-Sell Action in Q1</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVRDSQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Intra-Cellular Therapies Right Now?</h2><p>Before you consider Intra-Cellular Therapies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intra-Cellular Therapies wasn't on the list.</p><p>While Intra-Cellular Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ITCI

<p>Fmr LLC reduced its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 0.4% in Q4, now holding 11,076,445 shares valued at $925.1 million. Other hedge funds, including Vanguard and Norges Bank, also adjusted their positions. ITCI shares opened at $131.87, with a 12-month range of $64.09 to $131.98. The company reported a loss of $0.16 EPS, missing estimates, and had revenue of $199.22 million. Analysts maintain a "hold" rating with a consensus price target of $106.23.</p>

Fmr LLC Reduces Stock Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)